Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Gains from Sales and Divestitures (2024 - 2025)

Bioregenx has reported Gains from Sales and Divestitures over the past 2 years, most recently at $1.9 million for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures fell 68.37% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, down 68.37%, while the annual FY2025 figure was $1.9 million, 68.37% down from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $1.9 million at Bioregenx, down from $6.1 million in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $6.1 million in Q4 2024 and troughed at $1.9 million in Q4 2025.